Sandra Sanchez - Pharma Mar Global Head
| PHMMF Stock | USD 75.00 0.00 0.00% |
Insider
Sandra Sanchez is Global Head of Pharma Mar SAU
| Phone | 34 91 846 60 00 |
| Web | https://www.pharmamar.com |
Pharma Mar Management Efficiency
The company has return on total asset (ROA) of 0.1326 % which means that it generated a profit of $0.1326 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4705 %, meaning that it generated $0.4705 on every $100 dollars invested by stockholders. Pharma Mar's management efficiency ratios could be used to measure how well Pharma Mar manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Nobuyuki Mochinaga | Casio Computer Co | N/A | |
| Garry Kostiuk | Mill City Ventures | N/A | |
| Yehiam Shinder | Kaltura | N/A | |
| John Pence | Asure Software | 53 | |
| Khalid Fellahi | Western Union Co | 55 | |
| Joseph II | Mill City Ventures | 55 | |
| Tetsuro Izumi | Casio Computer Co | N/A | |
| Shannon Armbrecht | Western Union Co | N/A | |
| Shelly Swanback | Western Union Co | 51 | |
| Jin Nakayama | Casio Computer Co | N/A | |
| Randal Rudniski | Asure Software | N/A | |
| Sigal Srur | Kaltura | N/A | |
| Brad Windbigler | Western Union Co | N/A | |
| Michelle Swanback | Western Union Co | 51 | |
| Dror Dotan | Kaltura | N/A | |
| C Lo | NETGEAR | 67 | |
| Todd Waletzki | Asure Software | N/A | |
| Xi Wen | Senmiao Technology | 40 | |
| Haitao Liu | Senmiao Technology | 52 | |
| Chunhai Li | Senmiao Technology | 39 | |
| Heidi Cormack | NETGEAR | 49 | |
Management Performance
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 |
Pharma Mar SAU Leadership Team
Elected by the shareholders, the Pharma Mar's board of directors comprises two types of representatives: Pharma Mar inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharma. The board's role is to monitor Pharma Mar's management team and ensure that shareholders' interests are well served. Pharma Mar's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharma Mar's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pedro Puentes, Executive Vice Chairman | ||
| Jose SousaFaro, President CEO, Chairman of the Board | ||
| Sandra Sanchez, Global Head | ||
| Elena Crespo, Director of Finance - Oncology Business Unit | ||
| Jos MartinezLosa, Director Relations | ||
| Juan Nogues, Director Sales | ||
| Mara Caballero, Chief Officer | ||
| Juan Carretero, Founder | ||
| Lara Vadillo, Communication Director | ||
| Juan Pulido, Gen Directors |
Pharma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pharma Mar a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.47 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.35 % | |||
| Operating Margin | 0.33 % | |||
| Current Valuation | 1.12 B | |||
| Shares Outstanding | 18.09 M | |||
| Shares Owned By Insiders | 26.95 % | |||
| Shares Owned By Institutions | 10.48 % | |||
| Price To Earning | 7.38 X | |||
| Price To Book | 5.60 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Pharma Pink Sheet
Pharma Mar financial ratios help investors to determine whether Pharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pharma with respect to the benefits of owning Pharma Mar security.